Guggenheim Initiates Coverage on Enliven Therapeutics (NASDAQ:ELVN)

Guggenheim assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research note issued to investors on Tuesday. The firm set a “buy” rating and a $80.00 price target on the stock. Guggenheim’s target price points to a potential upside of 102.07% from the stock’s current price.

ELVN has been the topic of several other reports. HC Wainwright lifted their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. The Goldman Sachs Group lifted their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a report on Friday. Finally, Mizuho lifted their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, March 25th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $53.17.

Enliven Therapeutics Stock Down 2.8%

Shares of Enliven Therapeutics stock opened at $39.59 on Tuesday. Enliven Therapeutics has a 12 month low of $14.78 and a 12 month high of $48.53. The business has a fifty day simple moving average of $37.48 and a 200 day simple moving average of $27.59. The stock has a market cap of $2.41 billion, a PE ratio of -23.71 and a beta of 0.32.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Analysts expect that Enliven Therapeutics will post -1.7 EPS for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other news, Director Richard A. Heyman sold 1,230 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director directly owned 22,647 shares in the company, valued at $592,898.46. The trade was a 5.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Benjamin Hohl sold 10,000 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the sale, the chief financial officer owned 51,000 shares in the company, valued at approximately $1,508,580. This trade represents a 16.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Institutional investors have recently modified their holdings of the company. KBC Group NV bought a new stake in shares of Enliven Therapeutics in the first quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. Quantbot Technologies LP lifted its holdings in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares in the last quarter. Finally, AlphaQuest LLC bought a new stake in shares of Enliven Therapeutics in the third quarter valued at about $96,000. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.